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Abstract
Background: Cell-surface receptors play essential roles in anthrax toxin action by providing the toxin with a high-affinity
anchor and self-assembly site on the plasma membrane, mediating the toxin entry into cells through endocytosis, and
shifting the pH threshold for prepore-to-pore conversion of anthrax toxin protective antigen (PA) to a more acidic pH,
thereby inhibiting premature pore formation. Each of the two known anthrax toxin receptors, ANTXR1 and ANTXR2, has an
ectodomain comprised of an N-terminal von Willebrand factor A domain (VWA), which binds PA, and an uncharacterized
immunoglobulin-like domain (Ig) that connects VWA to the membrane-spanning domain. Potential roles of the receptor Ig
domain in anthrax toxin action have not been investigated heretofore.
Methodology/Principal Findings: We expressed and purified the ANTXR2 ectodomain (R2-VWA-Ig) in E. coli and showed
that it contains three disulfide bonds: one in R2-VWA and two in R2-Ig. Reduction of the ectodomain inhibited functioning
of the pore, as measured by K
+ release from liposomes or Chinese hamster ovary cells or by PA-mediated translocation of a
model substrate across the plasma membrane. However, reduction did not affect binding of the ectodomain to PA or the
transition of ectodomain-bound PA prepore to the pore conformation. The inhibitory effect depended specifically on
reduction of the disulfides within R2-Ig.
Conclusions/Significance: We conclude that disulfide integrity within R2-Ig is essential for proper functioning of receptor-
bound PA pore. This finding provides a novel venue to investigate the mechanism of anthrax toxin action and suggests new
strategies for inhibiting toxin action.
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Introduction
A common way for pathogenic bacteria to defend themselves
against the host’s immune system is to deliver a toxin into the
cytoplasm of host cells and disrupt key steps of metabolism. Most
intracellularly acting toxins are bipartite entities, in which one
part, the B (binding) moiety, binds to a cell surface receptor,
hijacks the receptor-mediated endocytosis pathway, and facilitates
delivery of the other part, the A (catalytic) moiety, to the cytosol
[1]. Study of the roles of receptors in toxin action is of interest in
understanding bacterial pathogenesis and in developing novel
therapeutics against infection.
Anthrax toxin is a tripartite system, composed of two catalytic
moieties, edema factor (EF) and lethal factor (LF), and a receptor-
binding/pore-forming moiety, protective antigen (PA). PA
(83 kDa) binds to cell-surface receptors and is cleaved by furin
or a furin-like protease to generate an active, 63-kDa form (PA63)
[2]. PA63 oligomerizes into a heptameric or octameric [3],
receptor- bound prepore, which contains high-affinity binding
sites for EF and LF[4]. The toxin-receptor complexes are
internalized by receptor-mediated endocytosis, and the prepore
moiety undergoes an acidic pH-dependent conformational
rearrangement within the endosome to form a cation-selective,
transmembrane pore [5]. The PA pore mediates translocation of
EF and LF across the endosomal membrane into the cytosol,
where, EF, an 89-kDa calmodulin-dependent adenylate cyclase,
elevates levels of cAMP [6], and LF, a 90-kDa zinc protease,
inactivates mitogen-activated proteins kinase kinases [7].
Two cellular receptors for PA have been identified: ANTXR1
[8] and ANTXR2 [9]. Recently, it has been shown that the
lethality of anthrax toxin for mice is primarily mediated by
ANTXR2 and that ANTXR1 plays only a minor role [10]. Both
receptors are widely expressed type-I transmembrane proteins,
which exhibit a high degree of similarity; each comprises an
extracellular domain (ectodomain), a single-pass transmembrane
domain, and a cytoplasmic domain (Figure 1A). PA binds to a
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10553von Willebrand Factor type A (VWA) domain located at the N
terminus of the ectodomain. While the physiological functions of
the receptors have not been fully elucidated, they bind to
extracellular matrix components and are associated with angio-
genesis [11–13]. Mutations in the ANTXR2 gene are linked to
two human autosomal recessive diseases, juvenile hyaline fibro-
matosis and infantile systemic hyalinosis [14–17].
A conserved metal ion-dependent adhesion site (MIDAS) within
R2-VWA, the VWA domain (residues 38–218) of ANTXR2,
binds PA with high affinity (Kd,170 pM when liganded by Mg
2+)
(Figure 1B) [18–20]. Binding to R2-VWA involves not only
domain 4 (receptor binding domain) of PA, but also domain 2
(pore-forming domain) [18]. The 2b2–2b3 loops (residues 303–
322) of the domains 2 of heptameric PA prepores move to the base
of the structure during the low pH-induced conformational
rearrangement and form a 14-strand transmembrane b-barrel
[21]. Binding of R2-VWA to the PA prepore shifts the pH
threshold of prepore-to-pore conversion to a more acidic pH range
[20,22]. Whole-cell voltage-clamp measurements of PA pore
current have shown that ANTXR2 mediates PA pore formation
Figure 1. ANTXR2 ectodomain is composed of R2-VWA and R2-Ig. A. Schematic of ANTXR2. ANTXR2 is composed of R2-VWA (VWA, 38–218)
and R2-Ig (Ig, 219–318), a single-pass transmembrane domain (TM, 319–343) and a cytoplasmic domain (Cyto, 344–489). B. The crystal structure of R2-
VWA domain (1SHU) as displayed in Swiss-PDB-Viewer. Residues Cys175, the Cys39–Cys218 disulfide bond, and Mn
2+ ion of MIDAS are shown and
labeled. C. Sequence alignment of the ectodomains of ANTXR1 (R1) and ANTXR2 (R2). The seven conserved Cys residues are highlighted and
numbered in R2. Identical residues are labeled with asterisk (*).
doi:10.1371/journal.pone.0010553.g001
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to acidic conditions [23].
While R2-VWA has been well characterized, the structure and
function of the domain (residues 219–318) downstream of R2-VWA
within the extracellular portion of ANTXR2 have not yet been
addressed. A reverse position-specific BLAST (RPS-BLAST) search
against the conserved domain database shows that this domain is a
member of the immunoglobulin (Ig) superfamily (pfam05587, here
termed R2-Ig) (Figure 1A). Within the ANTXR2 ectodomain,
there are seven Cys residues, with three on R2-VWA and four on
R2-Ig (Figure 1C). These residues are highly conserved among the
homologues of anthrax toxin receptors. Our current study indicates
that the integrity of the disulfide bonds in R2-Ig is essential for
proper functioning of the receptor-bound pore, and presumably for
receptor-mediated anthrax toxin action.
Materials and Methods
Cell Culture and Media
An anthrax toxin receptor-deficient CHO-R1.1 cell line that
stably expresses ANTXR2-GFP (termed CHO-ANTXR2) was a
gift from John A. T. Young [8,9]. The cells were grown in Ham’s
F-12 medium supplemented with 10% calf serum, 2 mM
glutamine, 500 units/ml penicillin, 500 units/ml streptomycin
sulfate, and 100 units/ml G418, under a humidified atmosphere
with 5% CO2.
Plasmid Construction and Protein Purification
The cDNA encoding residues 38–318 of ANTXR2 was
amplified by PCR and inserted into a pMAL-p2x vector (NEB)
at Xho I and Hind III sites with a His6-tag at the C-terminus
flanked by a thrombin cleavage site. The construct expresses a
fusion protein, MBP-ANTXR2(38–318)-His6. The fusion protein
was co-expressed with a bacterial disulfide isomerase, DsbC (a
kind gift from Jon Beckwith), in the periplasm of bacterial strain
BL21(DE3). Bacterial cells were inoculated in a 10 L-fermentor in
a rich medium at 37uC until OD600 reached ,10. The
temperature was shifted to 16uC and expression of the fusion
protein and DsbC were induced with 0.1 mM IPTG and 0.2%
arabinose, respectively, for overnight. The bacterial cells were
harvested, and the periplasmic fraction was prepared by osmotic
shock as previously described [20]. The fraction was passed
through a Ni-column and eluted with an imidazole gradient. The
eluted protein was concentrated, and the soluble monomeric form
of the fusion protein was further purified by gel filtration on a
Superdex-200 column. Subsequently, the MBP- and His6- tags
were removed by incubating the protein with Factor Xa and
thrombin, respectively. The recombinant PA and R2-VWA were
expressed and purified as described [20].
Estimation of free–SH group on R2-VWA-Ig with Ellman’s
reagent
Ellman’s reagent (5,59dithiobis(2-nitrobenzoic acid); DTNB;
500 mM) was incubated with 10 mM of R2-VWA-Ig (WT) or R2-
VWA-Ig (C175A) in 6 M guanidinium chloride and 0.1 M
TrisHCl (pH 8.0). The absorbance at 412 nm was recorded in a
spectrophotometer. Similarly, L-Cysteine at various concentra-
tions (0, 2.5, 5, 10, 20, 40, 80, 160 mM) was incubated with
500 mM of Ellman’s reagent in 6 M guanidinium chloride and
0.1 M TrisHCl (pH 8.0), and the absorbance at 412 nm was
recorded. These data were used to plot a standard curve. The
concentration of free–SH group ([-SH]) in the protein samples was
calculated based on the standard curve, and the number of–SH
group per molecule was calculated as [-SH]/[protein].
Gel Shift Assay for PA-Receptor Binding
PA83, R2-VWA, and R2-VWA-Ig were mixed (receptor/PA
ratio 2:1), as indicated, in 20 mM Tris-HCl (pH 8.5), 150 mM
NaCl, 1 mM MgCl2, with or without 10 mM TCEP, at room
temperature for 30 min. The samples were loaded onto 4–20%
acrylamide, Tris-glycine gels (Invitrogen). The running buffer was
25 mM Tris-base, 192 mM glycine. The gels were stained with
Coomassie blue. Note: treating with either DTT or TCEP before
or after receptor binding to PA gave the same results. Thus,
neither the choice of the reducing agent nor the timing of addition
of the reducing agent had any effect on the results.
SDS-Resistant PA63 Oligomer
To assay PA prepore to pore transition in solution, PA63
heptameric prepore, R2-VWA, and R2-VWA-Ig were mixed
(receptor/PA ratio 2:1), as indicated, in 20 mM Tris-HCl
(pH 8.5), 150 mM NaCl and 1 mM MgCl2, with or without
10 mM TCEP, at room temperature for 30 min. The solution was
acidified by the addition of 1/10 volume of 1 M sodium acetate
(pH 5.0) and incubated for 10 min. Samples were exposed to
1.25% SDS for 20 min and electrophoresed on SDS-PAGE, and
the bands were visualized after Coomassie staining. To assay PA
prepore to pore transition on the plasma membrane, CHO-
ANTXR2 cells were incubated with PA63 prepore (10 mg/ml),
with or without 10 mM DTT or TCEP, for 1 h at 4uC. The cells
were washed with cold PBS and incubated in 150 mM NaCl,
20 mM Mes, 5 mM gluconic acid (pH 5.0) for 10 min at 4uC. The
cells were then harvested and exposed to 1.25% SDS at 100uC for
10 min. The samples were subjected to SDS-PAGE followed by
Western blotting with a goat anti-PA antibody (List Biolab), mouse
anti-goat horseradish peroxidase (Santa Cruz), and SuperSignal
Western detection reagent (Pierce).
Liposome Preparation
Liposomes were prepared as previously described [24]. Briefly,
DOPC in chloroform(Avanti Polar Lipids) was dried under N2 gas to
form a lipid film, followed by vacuum for 3 h to remove residual
solvent. The dried lipid film was rehydrated with buffer to form
multilamellar vesicles and subjected to six freeze-thaw cycles and
extrusion through a 200-nm pore size polycarbonate filter (Nucleo-
pore) in a mini extruder (Avanti Polar Lipids). The protocol yielded
large unilamellar vesicles with an average diameter of 150–200 nm.
K
+ Release From Liposomes and Cells
Liposome containing 150 mM KCl, 10 mM Hepes (pH 7.4)
were transferred into 150 mM NaCl, 20 mM Tris-HCl (pH 8.5)
by buffer exchange. The liposome was added to K
+ release buffer
(50 mM sodium acetate, 150 mM NaCl, pH 5.0) and after 1 min,
PA prepore (3 nM) complexed with either R2-VWA or R2-VWA-
Ig (40 nM) was added. The receptor proteins were treated with
10 mM DTT or TCEP before or after incubating with PA
prepore. The solution was stirred continuously with a magnetic
stirrer, and K
+ release was monitored with a K
+-selective electrode
(Orion Research).
PA-Mediated LFN Translocation Across the Plasma
Membrane
As described [25,26], CHO-ANTXR2 cells were incubated with
PA (10 mg/ml) for 2 h at 4uC, with or without the reducing agents.
Cells were then washed with cold PBS to remove unbound protein,
and
35S-LFN, produced from TNT coupled reticulocyte lysate
system (Promega), was added. The cells were then incubated for 2 h
at 4uC, with or without the reducing agents. The unbound
35S-LFN
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35S-LFN translocation was triggered
by acidification of the cells with pH 5.0 buffer [150 mM NaCl,
20 mM Mes, 5 mM gluconic acid (pH 5.0)] at 37uCf o r2m i n s .
Pronase (2 mg/ml) was added to remove LFN remaining on the cell
surface after translocation. The cells were harvested, and the lysates
were applied to SDS-PAGE followed by autoradiography.
Results
Purification of recombinant ANTXR2 ectodomain, R2-
VWA-Ig, from E. coli
To express soluble, functional ectodomain of ANTXR2 in E.
coli and facilitate its purification, we engineered a construct that
expressed a MBP-ANTXR2(38–318)-His6 fusion protein in the
bacterial periplasm, where disulfide bond formation is favored.
Co-expression of this construct with a bacterial disulfide isomerase,
DsbC, at low temperature increased the yield of soluble protein.
After affinity purification through a Ni-column, the MBP- and
His6- tags were removed with Factor Xa and thrombin,
respectively. The purified protein ran at ,30 kDa on a size
exclusion column (Figure 2A) and on SDS-PAGE (Figure 2B),
consistent with the calculated molecular weight of a monomer.
The amino acid sequence of the purified protein was confirmed by
MALDI-TOF analysis, with .93% peptide recovery (data not
shown). When DTT (final concentration, 10 mM) was added to
the sample, the protein migrated more slowly in SDS-PAGE,
consistent with the reduction of intra-molecular disulfide bonds
(Figure 2B). The ANTXR2 ectodomain has seven Cys residues in
total with three on R2-VWA and four on R2-Ig (Figure 1C). In
the crystal structure of R2-VWA, Cys39 and Cys218 are linked by
a disulfide bond, while Cys175 is unpaired and buried within the
structure (Figure 1B) [18,19]. Subsequently, an assay with
Figure 2. Purified ANTXR2 ectodomain, R2-VWA-Ig, is a soluble monomeric protein containing three disulfide bonds. A. Gel filtration
of the purified R2-VWA-Ig. R2-VWA-Ig was expressed and purified as a fusion protein with an N-terminal MBP tag and a C-terminal His6-tag. After
removal of the MBP- and His6- tags, R2-VWA-Ig ran as a monomer (,30 kDal) in a Superdex-75 column in 20 mM TrisHCl (pH 8.0) and 150 mM NaCl.
B. SDS-PAGE of the purified R2-VWA-Ig. The purified R2-VWA-Ig was treated with or without 10 mM DTT in SDS sample buffer, and run on SDS-PAGE.
C. left panel, cysteine standard curve; at OD412 was plotted after L-cysteine at various concentrations was incubated with 500 mM DTNB in 6 M
guanidium HCl and 0.1 M TrisHCl, pH 8.0; right panel, 10 mM of R2-VWA-Ig (WT) or R2-VWA-Ig (C175A) was incubated with 500 mM DTNB in 6 M




PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10553Figure 3. Disulfide reduction of R2-VWA-Ig did not affect receptor-PA binding. PA83, R2-VWA, and R2-VWA-Ig were mixed, as indicated in
20 mM Tris-HCl (pH 8.5), 150 mM NaCl, 1 mM MgCl2, in the presence or absence of 10 mM TCEP. The samples were subjected to native gel
electrophoresis followed by Coomassie blue staining.
doi:10.1371/journal.pone.0010553.g003
Figure 4. Disulfide reduction did not affect formation of SDS-resistant PA63 oligomers at low pH. A. PA prepore, R2-VWA, and R2-VWA-
Ig were mixed as indicated (receptor/PA ratio is 2/1) in 20 mM Tris-HCl (pH 8.5), 150 mM NaCl, 1 mM MgCl2, in the presence or absence of 10 mM
TCEP. Acidification was initiated by addition of 1/10 volume 1 M sodium acetate (pH 5.0). The samples were subjected to SDS-PAGE and stained with
Coomassie blue. B. PA prepore was incubated at 4uC with CHO-ANTXR2 cells in the presence or absence of reducing agents (10 mM DTT or TCEP as
indicated). The cells were washed to remove unbound PA, and acidification was initiated by addition of a pH 5.0 buffer into the cell cultures. After
10 min at 4uC the cells were harvested, and lysates were applied to SDS-PAGE, followed by western blotting with anti-PA antibody.
doi:10.1371/journal.pone.0010553.g004
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content of R2-VWA-Ig against a series of Cys amino acid
standards (Figure 2C). The results suggested that wild type R2-
VWA-Ig contains one reactive–SH group per molecule, while the
mutant R2-VWA-Ig (C175A) has none. Therefore, the four Cys
residues within the R2-Ig domain (C230, C255, C279, and C315)
presumably form two disulfide bonds. Replacing the Cys residues
in R2-Ig with Ala residues resulted in expression of the
ectodomain in the form of inclusion bodies in E. coli (data not
shown).
Reduction of the ectodomain does not affect its ability to
bind PA
R2-VWA and R2-VWA-Ig were tested in a gel shift assay to
assess their ability to bind to PA under oxidizing and reducing
conditions. Without reducing agent, both R2-VWA and R2-
VWA-Ig bound PA, as evidenced by a shift in PA migration in
native gel electrophoresis (Figure 3). Treatment with reducing
agent did not affect binding of R2-VWA or R2-VWA-Ig to PA,
even when the treatment was initiated before incubation with PA.
TCEP-treated R2-VWA-Ig ran as a smear, suggesting formation
of heterogeneous oligomers of R2-VWA-Ig during electrophoresis,
and the complexes with PA showed a similar, smeared pattern.
The disulfide bond Cys39-Cys218 in R2-VWA had been shown
earlier not to be required for PA binding, given that a truncated
variant of R2-VWA (residues 40–217, without the disulfide bond)
had nearly identical crystal structure and affinity for PA, as wild
type R2-VWA (residues 38–218, with the disulfide bond) [18,20].
We conclude that the integrity of disulfide bonds in the R2-VWA-
Ig is not required for receptor-PA binding.
Without reducing agents the recombinant R2-VWA-Ig protein
ran as a single monodisperse peak in gel filtration and migrated as
a single band in SDS-PAGE (Figure 2A and B). However, the
protein appeared as a doublet in native gel electrophoresis
(Figure 3). The basis of this molecular heterogeneity in native
gel electrophoresis is not clear and may be related to disulfide
isomerization in R2-Ig.
Reduction does not affect formation of SDS-resistant
PA63 oligomers
Coincident with the conformational transition of heptameric
prepore to pore, triggered by acidic pH, the soluble oligomeric
PA63 prepore is transformed into an SDS-resistant form
[22,27,28], and this transformation may be used to monitor the
transition. While no SDS-resistant PA63 oligomer was observed at
pH 8.5, prepore alone, prepore complexed with R2-VWA, and
prepore complexed with R2-VWA-Ig were converted to SDS-
resistant PA63 oligomers at pH 5.0 in the presence or absence of
reducing agent (TCEP), as determined by SDS-PAGE
(Figure 4A). In addition, we tested whether reduction of disulfides
of ANTXR2 affected the conformational transition of prepore to
pore on the plasma membrane. We used an anthrax toxin
receptor-deficient CHO cell line that stably expressed ANTXR2-
EGFP (CHO-ANTXR2) [9]. PA prepore was incubated with the
cells at 4uC to minimize receptor-mediated endocytosis and
maintain PA prepore at the cell surface. Addition of acidic buffer
(pH 5.0) to the medium triggered the prepore to pore transition, as
evidenced by formation of SDS-resistant PA63 oligomers
(Figure 4B), and this transition was unaffected by DTT or
TCEP. Data in Figure 5 imply that disulfides in ANTXR2-EGFP
were in fact reduced under the conditions employed. Note that the
reducing agents had no effect on PA binding to the ANTXR2 on
the cell surface (Figure 4B).
Disulfide reduction of R2-VWA-Ig inhibits the release of
K
+ through the PA pore
As a test of pore function we measured release of K
+ through
PA pores formed in liposomal membranes with PA prepore bound
to R2-VWA-Ig (Figure 5A). In an earlier communication we
showed that binding of R2-VWA to the prepore inhibited
aggregation of the pore complexes in solution at low pH, and
thereby promoted partitioning of PA into liposomal membranes
and formation of ion-permeable pores [24]. Consistent with the
previous result, prepore complexed with R2-VWA (PA/R2-VWA)
induced greater release of K
+ than prepore alone. In the absence
of reducing agent, prepore complexed with R2-VWA-Ig (PA/R2-
Figure 5. Disulfide reduction of R2-VWA-Ig inhibited release of
K
+.A . PA prepore, R2-VWA, and R2-VWA-Ig were incubated as indicated
(receptor/PA ratio=2/1) in 20 mM Tris-HCl (pH 8.5), 150 mM NaCl,
1 mM MgCl2, in the presence or absence of 10 mM TCEP. Release of K
+
ions from KCl-charged liposomes was monitored with a K
+-selective
probe in the solution. B. PA prepore (10 mg/ml) was incubated at 4uC
with CHO-ANTXR2 cells, with various concentrations of TCEP as
indicated. The cells were washed with 20 mM Tris-HCl (pH 8.0) and
150 mM NaCl to remove unbound PA, and acidification was initiated by
addition of a pH 5.0 buffer into the cell cultures at 4uC for various times.
The supernatants were collected and the content of K
+ ion was
measured by the K
+-selective probe and read with a pH meter as mV.
DNI, a PA dominant negative mutant that is defective in pore formation,
served as negative control.
doi:10.1371/journal.pone.0010553.g005
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+ to a similar level as prepore complexed with
R2-VWA. However, reducing agent significantly inhibited K
+
release by PA/R2-VWA-Ig, but not by PA/R2-VWA. Note that
in the presence of TCEP, K
+ release by PA/R2-VWA-Ig was even
lower than that by prepore alone. This finding indicates that
reduction of disulfide bonds in the R2-Ig domain, but not that in
R2-VWA, inhibits release of K
+ through PA pore.
We also tested the effect of the reducing agents on K
+ release
through PA pores formed on the plasma membrane of CHO-
ANTXR2 cells (Figure 5B). After prepore was bound to
ANTXR2 on the cell surface, acidification induced K
+ release
from the cells in a time-dependent manner. DNI, a double PA
mutant (K397D, D425K) known to be strongly defective in pore
formation [29,30], failed to induce K
+ release under the same
conditions. K
+ release by cell-bound wild-type prepore was
inhibited by TCEP in a dose- and concentration-dependent
manner, even if the cells were treated with the reducing agent after
PA binding. Thus, disulfide reduction of the R2-Ig domain
inhibited the release of K
+ through PA pore both in liposomes and
in a cellular system.
Disulfide reduction inhibits PA-mediated LFN
translocation across the plasma membrane
The effects of DTT and TCEP on K
+ release through PA pore
prompted us to test effects of receptor disulfide reduction on
anthrax toxin-mediated cytotoxicity. In a previously developed
assay, PA mediates translocation of LFN-DTA, a fusion protein
composed of LF PA-binding domain and diphtheria toxin A
domain, across the endosomal membranes to the cytosol, where
LFN-DTA inhibits protein synthesis ([
3H]-leucine incorporation)
[31,32]. However, this assay was hampered by the fact that the
reducing agents alone (TCEP and DTT) significantly inhibited
protein synthesis under the assay conditions used. Thus, as an
alternative we tested whether the reducing agents inhibited PA
pore-mediated LFN translocation across the plasma membrane.
We used a pronase protection assay [25,26]. Briefly,
35S-LFN is
bound to PA prepore on the cell surface, and upon exposure of the
cells to low pH, the labeled protein translocates across the plasma
membrane and becomes inaccessible to added pronase. As shown
in Figure 6, both reducing agents strongly inhibited PA-mediated
LFN translocation. Note that, without pronase, equivalent
amounts of LFN were detected in the cell lysate with or without
the reducing agents, indicating that LFN binding to PA-receptor
complexes on the cell surface was not compromised by reduction
of the receptor disulfides.
Discussion
PA binds to cell surface receptors, hijacks receptor-mediated
endocytosis pathways, and forms a protein conductive pore on the
endosomal membrane. ANTXR2 provides the toxin with a high-
affinity anchor and self-assembly site on the plasma membrane
and guides its entry into cells; and further the receptor functions as
a molecular clamp that shifts the pH threshold of prepore-to-pore
conversion to a more acidic pH, thereby preventing premature
pore formation before the toxin reaches a suitable compartment.
In the present study we have shown that reduction of the
ectodomain of the receptor blocks proper functioning of the PA
pore. This finding suggests that anthrax toxin action is sensitive to
redox conditions and raises the possibility that toxin action may be
modulated by reductants to which it is exposed during endocytosis
and intracellular trafficking.
A conserved domain search showed that the ectodomain of
ANTXR2 contains two distinct domains, R2-VWA and R2-Ig.
Based on the crystal structure of R2-VWA and measurements with
Ellman’s reagent, we predict that R2-VWA-Ig contains three
disulfide bonds—one in R2-VWA and two in R2-Ig—plus a
buried free Cys, Cys175, in R2-VWA. We found in the absence of
reducing agents that R2-VWA-Ig, like isolated R2-VWA, bound
PA (Figure 3) and enhanced the release of K
+ from liposomes
(Figure 5A). R2-VWA-Ig retained the ability to bind to PA in the
presence of reducing agents (Figure 3), consistent with the fact
that the disulfide bond C39-C218 in R2-VWA is not required for
PA binding [19,20]. These data support our predicted distribution
of disulfides in the two domains and suggest that the VWA domain
behaves the same within the context of R2-VWA-Ig as it does as
an isolated domain.
We found a strong inhibitory effect of reduction of R2-VWA-Ig
on PA-mediated release of K
+ from liposomes, whereas PA
binding and conversion of bound prepore to the SDS-resistant
state were insensitive to this modification. Furthermore, treatment
of CHO-ANTXR2 cells with reducing agents blocked PA-
dependent K
+ release and PA-dependent translocation of LFN
across the plasma membrane. Reduction did not compromise LFN
binding to PA-receptor complexes on the cell surface, suggesting
that the inhibition of PA-dependent K
+ release and translocation
Figure 6. Reducing agents inhibited PA-mediated LFN translocation across the plasma membrane. PA prepore was incubated with CHO-
ANTXR2 cells at 4uC followed by the addition of
35S-LFN to the cells. The cells were treated with 10 mM DTT or TCEP, as indicated. Translocation was
triggered by addition of a pH 5.0 buffer to the cells. The cells were either directly lysed (pronase2) or treated with pronase (pronase+) followed by
lysis.
35S-LFN was detected by autoradiography.
doi:10.1371/journal.pone.0010553.g006
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ectodomain.
How might reduction of disulfides in R2-VWA-Ig, and
specifically in the R2-Ig domain, block pore function? Presumably
reduction relieves conformational constraints on R2-Ig that
prevent unfolding. Concurrent unfolding of the multiple copies
of R2-VWA-Ig receptor bound to prepore might allow any of
several possible inhibitory interactions. Because PA contains no
Cys residues, there is no possibility of anomalous disulfides being
formed between PA and reduced R2-VWA-Ig. However,
noncovalent interactions between reduced receptor and PA, either
during or following the conformational transition from the prepore
to the pore, could interfere with formation of functional pore or its
insertion into a membrane. Alternatively, interactions among the
several reduced receptors bound to the pore, including intermo-
lecular disulfide formation and/or noncovalent interactions, could
generate a physical barrier to insertion of the pore into the
membrane. It seems unlikely that the pore would form abortively
due to an increase in the distance between the prepore and the
membrane allowed by receptor unfolding, in view of the inhibitory
effect on K
+ release from liposomes, where the assay involves
conformational transition of the R2-VWA-Ig:prepore complexes
in solution.
Current concepts of the redox potentials within intracellular
compartments support the notion that the endosomal lumen could
be either oxidizing or reducing, depending on various endocytic
pathways [33,34]. It is believed that anthrax toxin-ANTXR2
complex traffics to late endosomes, where low-pH induces
conformational transition of PA prepore-to-pore and translocation
of LF/EF to the cytosol [35,36], but which endocytic pathway
ANTXR2 mediates the trafficking and the roles of cellular redox
regulators in toxin action are not clear. The present study provides
a novel venue to investigate the mechanism of anthrax toxin action
and suggests novel strategies for anthrax toxin inhibition.
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